TABLE 1.

Direct medical cost and health effect input parameters

	Parameter	Base	Distribution	First parameter (α for beta, shape for gamma, minimum for beta‐PERT)	Second parameter (β for beta, scale for gamma, maximum for beta‐PERT)	Reference
Diagnostic and treatment costs (€)	Total screening cost, low‐risk groups a	15.00	Beta‐PERT	7.50	30.00	Sum of price of HCV antibody test b and per‐screen implementation cost c , assuming half the total cost as minimum and double the total cost as maximum
	Total screening cost, high‐risk groups a	55.00	Beta‐PERT	27.50	110.00	Sum of price of HCV antibody test b and per‐screen implementation cost c , assuming half the total cost as minimum and double the total cost as maximum
	RNA test/PCR	63.01	—	—	—	Ministero della Salute 2013 (code 91.19.3)
	Genotyping	77.47	—	—	—	Ministero della Salute 2013 (code 91.20.2)
	Fibroscan	50.00	—	—	—	10, 11
	Lab costs	50.00	—	—	—	10, 11
	Antiviral treatment	4000.00	—	—	—	10, 11
Healthcare costs (€)	Fibrotic (F0‐F3)	—	Gamma	100.00	2.77	10, 11
	Comp. cirrhosis	—	Gamma	100.00	8.76	10, 11
	DCC	—	Gamma	100.00	66.26	10, 11
	HCC	—	Gamma	100.00	128.96	10, 11
	LTx, first year	—	Gamma	100.00	737.74	10, 11
	LTx, subs years	—	Gamma	100.00	23.65	10
	Death	—	—	—	—	11
	Post‐SVR monitoring for cirrhotic patients	50.00	—	—	—	Cost of one ultrasound
QALY utilities, pre‐SVR	Fibrotic (F0‐F3)	—	Beta	11.12	1.52	12
	Comp. cirrhosis	—	Beta	16.17	3.31	12
	DCC	—	Beta	26.27	9.72	12
	HCC	—	Beta	46.47	41.21	12
	LTx, first year	—	Beta	26.27	9.72	12
	LTx, subs years	—	Beta	26.27	9.72	12
	Healthy	1	—	—	—	12
QALY utilities, post‐SVR	Fibrotic (F0‐F3)	1	—	—	—	12
	Comp. cirrhosis	Same as pre‐SVR
	DCC	Same as pre‐SVR
	HCC	Same as pre‐SVR
	LTx, first year	Same as pre‐SVR
	LTx, subs years	Same as pre‐SVR

Abbreviations: comp. cirrhosis, compensated cirrhosis; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LTx, subs years, liver transplant, subsequent years; LTx, liver transplant; PCR, polymerase chain reaction; QALY, quality‐adjusted life year; RNA, ribonucleic acid; SVR, sustained virologic response.

^aUncertainty in input considered in the most cost‐effective scenario.

^bAssumption and [ ¹⁸ ].

^cAssumption.